Contents of this document
Earnings presentation materialsThird quarter of the fiscal year ended December 20257 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥37,086 million+5.0%
Operating profit¥2,619 million+1,500.0%
Ordinary income¥2,144 million
Net income¥-380 million
Selling, general and administrative expenses¥23,246 million
Gross Profit Margin
Rate70 %
Year-on-year change (points)0 %
Results for the three months of the current quarter
Net Sales
¥12,533 million
Operating profit
¥982 million
Ordinary income
¥972 million
Net income
¥179 million
Adjusted EBITDA
¥1,950 million
Full-year earnings forecast
Net Sales
¥50,000 million
Adjusted EBITDA
¥7,000 million
Operating profit
¥3,200 million
Progress against full-year forecast 通期の予想に対して、いまどこまで進んだかの割合です。
Net Sales74 %
Adjusted EBITDA88 %
Operating profit109 %
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
売上高は概ね計画通り、利益は計画を大幅に上回るペースBreakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
調整後EBITDA_事業別サティス製薬の連結寄与、価格改定、広告投資効率化、原価率・販売費率改善、子会社売却、実証プラント稼働終了、全社費用等を金額付きブリッジで表示
調整後EBITDA_科目別M&A影響143百万円、売上総利益942百万円、広告宣伝費30百万円、その他販売費656百万円、人件費200百万円、管理費145百万円、研究開発費121百万円、助成金収入26百万円など
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
商業プラント稼働開始2028年下期予定
Biofuel price
300 yen/L
Notes収益ポテンシャル試算の前提
Foreign Exchange
¥150 /US$
Notes収益ポテンシャル試算の前提
New initiatives
- AIを活用した生活習慣提案サービス『myme』のローンチ
- 『いきものたちにユーグレナ』ブランドで有機肥料・培養土を発売
- プロラボHDとの健康粉末飲料『MO ZYME』共同開発
- パラミロン高配合の新商品の発売
- エポラ社出雲工場でのハラール認証取得
- ゲノム編集ユーグレナの食品用途実証事業への採択
- マレーシアのバイオ燃料商業プラント建設の本格化
Key KPIsA metric the company considers important as a management benchmark.
- Number of group direct-to-consumer subscription customers71 10,000 people
- からだにユーグレナ定期顧客数Year on year against the same period last year+7.0%
- CONC定期顧客数Year on year against the same period last year+57.0%
- epo定期顧客数Year on year against the same period last year+22.0%
- 欧州バイオ燃料価格1.9 US$/L
Segment results
Healthcare
Net Sales
¥34,561 million
Adjusted EBITDA
¥6,817 million
Revenue_yoy_pct5
Adjusted EBITDA_yoy_pct37
Biofuels
Net Sales
¥716 million
Other
Net Sales
¥1,808 million
Number of employees
1,168 people
As ofEnd of December 2024
| Item | Details |
|---|---|
| Document type | Earnings presentation materials |
| Fiscal Period Covered | Third quarter of the fiscal year ended December 2025 |
| Net Sales | ¥37,086 million (YoY +5.0%) |
| Operating profit | ¥2,619 million (YoY +1,500.0%) |
| Ordinary income | ¥2,144 million |
| Net income | ¥-380 million |
| Gross Profit Margin | Rate 70 % / Year-on-year change (points) 0 % |
| Selling, general and administrative expenses | ¥23,246 million |
| Results for the three months of the current quarter | Net Sales ¥12,533 million / Operating profit ¥982 million / Ordinary income ¥972 million / Net income ¥179 million / Adjusted EBITDA ¥1,950 million |
| Full-year earnings forecast | Net Sales ¥50,000 million / Adjusted EBITDA ¥7,000 million / Operating profit ¥3,200 million |
| Progress against full-year forecast | Net Sales 74 % / Adjusted EBITDA 88 % / Operating profit 109 % |
| Self-assessment against the plan | 売上高は概ね計画通り、利益は計画を大幅に上回るペース |
| Segment results | Healthcare Net Sales ¥34,561 million / Adjusted EBITDA ¥6,817 million / Revenue_yoy_pct 5 / Adjusted EBITDA_yoy_pct 37 / Biofuels Net Sales ¥716 million / Adjusted EBITDA Not disclosed / Other Net Sales ¥1,808 million |
| Breakdown of Factors Affecting the Change | 調整後EBITDA_事業別 サティス製薬の連結寄与、価格改定、広告投資効率化、原価率・販売費率改善、子会社売却、実証プラント稼働終了、全社費用等を金額付きブリッジで表示 / 調整後EBITDA_科目別 M&A影響143百万円、売上総利益942百万円、広告宣伝費30百万円、その他販売費656百万円、人件費200百万円、管理費145百万円、研究開発費121百万円、助成金収入26百万円など |
| Key KPIs | Indicator name Number of group direct-to-consumer subscription customers / Value 71 10,000 people / Year on year against the same period last year Not disclosed, Indicator name からだにユーグレナ定期顧客数 / Value Not disclosed / Year on year against the same period last year 7, Indicator name CONC定期顧客数 / Value Not disclosed / Year on year against the same period last year 57, Indicator name epo定期顧客数 / Value Not disclosed / Year on year against the same period last year 22, Indicator name 欧州バイオ燃料価格 / Value 1.9 US$/L / Year on year against the same period last year Not disclosed |
| Number of employees | 1,168 people |
| Assumptions Underlying the Business Outlook | 商業プラント稼働開始 2028年下期予定 / Biofuel price 300 yen/L / Foreign Exchange ¥150 /US$ |
| New initiatives | AIを活用した生活習慣提案サービス『myme』のローンチ, 『いきものたちにユーグレナ』ブランドで有機肥料・培養土を発売, プロラボHDとの健康粉末飲料『MO ZYME』共同開発, パラミロン高配合の新商品の発売, エポラ社出雲工場でのハラール認証取得, ゲノム編集ユーグレナの食品用途実証事業への採択, マレーシアのバイオ燃料商業プラント建設の本格化 |
Items this document does not state (13)
Operating profit marginUnit price and quantity metricsNumber of stores and locationsRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.